Last reviewed · How we verify
NCT06342362
Magnesium Sulfate in Neonatal HIE"
Phase 4 trial testing Magnesium sulfate in Neonates With HIE in 102 participants. Status unknown.
2 October 2024
Quick facts
| Lead sponsor | Sindh Institute of Child Health and Neonatology |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | prevention |
| Enrollment | 102 |
| Start date | 2 April 2024 |
| Primary completion | 2 October 2024 |
| Estimated completion | 2 December 2024 |
| Sites | 1 location across Pakistan |
Drugs / interventions tested
- Magnesium sulfate — full drug profile →
- placebo or standard treatment)
Conditions studied
- Neonates With HIE — all drugs for Neonates With HIE →
Sponsor
Sindh Institute of Child Health and Neonatology
Who can join
Adults 1 Day to 30 Days, any sex, with Neonates With HIE. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study will investigates the neuroprotective effects of intravenous magnesium sulfate in neonates with hypoxic-ischemic encephalopathy (HIE) at a Karachi tertiary care hospital. Using a randomized clinical trial design, the study targets term and near-term newborns with moderate to severe HIE. Data collection involves obtaining informed consent, preparing and administering magnesium sulfate, and assessing outcomes including mortality and morbidity. The study aims to provide insights into improving patient outcomes and clinical practice for neonatal HIE management.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Pharmacological Therapies for Consequences of Perinatal Hypoxic-Ischemic Brain Injury: Where Are We Now?
Gebala P, Janowska J, Sypecka J. · · 2025 · PMID 41155490 · DOI 10.3390/ijms262010200 -
Antioxidant Therapy in Neonatal Hypoxic Ischemic Encephalopathy: Adjuvant or Future Alternative to Therapeutic Hypothermia?
Notarbartolo V, Badiane BA, Angileri VM, Piro E, et al · · 2024 · PMID 39590867 · DOI 10.3390/metabo14110630
Verify or expand the search:
- PubMed search for NCT06342362
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Magnesium sulfate
Trials testing the same drug.
- NCT07524972 — Antenatal Magnesium Sulphate in High-Risk Preterm Patients · Phase 3 · recruiting
- NCT07438366 — Adding Magnesium Sulphate to Combined Pectointercostal Plane and Erector Spinae Plane Blocks for Acute and Chronic Post- · NA · not yet recruiting
- NCT07213037 — Magnesium Sulfate Versus Lidocaine as Additives to Dexmedetomidine for Cough Suppression After Functional Endoscopic Sin · Phase 3 · not yet recruiting
- NCT06979141 — Dexmedetomidine, Magnesium Sulphate and Lidocaine for Cough Suppression After General Anesthesia · Phase 3 · recruiting
- NCT07131033 — Esketamine Combined With Magnesium Sulfate for Postoperative Fatigue Syndrome in Patients Undergoing Laparoscopic Cholec · Phase 1, PHASE2 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06342362 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sindh Institute of Child Health and Neonatology
- Last refreshed: 2 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06342362.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing